SeaStar Medical (ICU) Q2 2026 earnings review
Commercial Traction Eclipsed by Imminent Cash Cliff
SeaStar Medical is demonstrating clear commercial execution with its pediatric QUELIMMUNE therapy. Q2 revenue accelerated 82% YoY to $0.62 million, and gross margins remain stellar at 91%. However, the core investment thesis relies entirely on the adult NEUTRALIZE-AKI trial (currently 223/339 patients enrolled). With R&D expenses surging to fund this trial, net loss expanded to $3.7 million in Q2. The balance sheet is flashing red: the company holds just $7.0 million in cash against an operating burn rate that implies less than six months of runway. Dilution is practically guaranteed before the pivotal trial data reads out in mid-2027.
🐂 Bull Case
QUELIMMUNE adoption is accelerating. Adding 3 top-tier children's hospitals brings the total to 20, pushing first-half 2026 revenue to $1.11M. The 91% gross margin proves outstanding unit economics.
The NEUTRALIZE-AKI trial for the adult market—estimated to be 50x larger than pediatric—is 65% enrolled. A positive result unlocks a massive addressable market and positions the company as an acquisition target.
🐻 Bear Case
The company has $7.0M in cash but burned $5.75M in operating cash flow over the first six months of 2026. A highly dilutive equity raise or expensive debt issuance is unavoidable before the pivotal adult trial concludes.
Management's target to complete adult trial enrollment previously cited 'end of 2026' but now reads 'around year end or into the first quarter of 2027.' In biotech, timeline slippage destroys cash runway.
⚖️ Verdict: 🔴
Bearish near-term. The technology shows remarkable clinical promise and commercial traction, but the catastrophic cash position outweighs operational progress. Investors stepping in now will likely face severe dilution.
Key Themes
Cash Runway Reaching Critical Levels
Cash and equivalents fell from $12.0M at the end of 2025 to $9.3M in Q1 2026, and now sit at just $7.0M. First-half 2026 operating cash burn was $5.75M. Given the $3.7M net loss this quarter—driven primarily by trial expenses—the company lacks the capital to independently reach its expected mid-2027 data readout.
QUELIMMUNE Revenue Accelerating
Q2 net revenue jumped 82% YoY to $615K. The company successfully added 3 new top-rated children's hospitals in the quarter, bringing the total base to 20. With $1.11M in first-half revenue, SeaStar is tracking cleanly toward its $2M full-year target. The grassroots, KOL-driven sales strategy is efficiently converting medical centers.
Standardized Billing Catalyst via ICD-10-PCS
SeaStar secured dedicated ICD-10-PCS codes from CMS, effective October 1, 2026. This is a massive structural driver. By enabling standardized inpatient billing for the SCD therapy, the company removes a significant administrative bottleneck that has historically slowed hospital purchasing and adoption.
NEUTRALIZE-AKI Progress and Slight Delay
The pivotal adult AKI trial has enrolled 223 of 339 patients (up from 198 at the end of Q1). However, guidance on enrollment completion has subtly shifted from a firm 'end of 2026' to 'around year end or into the first quarter of 2027.' Any delay pushes back the modular PMA application timeline, extending the period the company must survive on limited pediatric revenues.
R&D Expense Ramp Accelerating Losses
Research and development expenses spiked 143% YoY to $2.52M in Q2 (up from $1.04M). Management attributes this directly to clinical trial scaling and personnel costs. With 100+ patients still to enroll in NEUTRALIZE-AKI and a new cardiorenal syndrome trial spinning up, these costs will not decelerate anytime soon.
Other KPIs
Remains exceptionally strong and stable (down marginally from 92% YoY). The selective cytopheretic device (SCD) costs very little to manufacture relative to its pricing, proving that if SeaStar can secure adult approval, operating leverage will be tremendous.
Accelerating significantly, up 78% from $1.03M YoY. Driven by increased compensation, legal/professional fees, and SEC-related expenses. Management needs to aggressively contain overhead given the cash position.
Guidance
Decelerating. Prior guidance firmly pointed to the end of 2026. Slipping into Q1 2027 indicates potential enrollment friction, meaning top-line data won't arrive until mid-to-late 2027.
Stable. Maintained from prior periods implicitly through 1H 2026 outperformance ($1.11M booked). Represents roughly 62% YoY growth from FY25's $1.23M.
Key Questions
Capital Strategy
With $7 million in cash and a quarterly burn of $3.7 million, how does management intend to fund operations through the mid-2027 NEUTRALIZE-AKI data readout without enacting highly dilutive equity raises?
Trial Enrollment Bottlenecks
The timeline for completing the 339-patient NEUTRALIZE-AKI trial has drifted slightly into Q1 2027. Are you seeing site fatigue, tighter screening failures, or other friction in adding these final 116 patients?
ICD-10-PCS Code Impact
With the new billing codes taking effect on October 1, 2026, do you expect a measurable reduction in the sales cycle length for onboarding new pediatric hospitals, and have any waitlisted hospitals indicated this as a condition for adoption?